8-K Announcements
6Material company update
Apr 22, 2026·SEC
Material company update
Feb 9, 2026·SEC
Material company update
Oct 22, 2025·SEC
Medpace Holdings, Inc.(MEDP)Earnings, Financials & Key Ratios
MEDP•NASDAQ
30.1× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryContract Research and Preclinical Services
AboutMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.Show more
- Revenue$2.53B+20.0%
- EBITDA$563M+18.3%
- Net Income$451M+11.6%
- EPS (Diluted)15.28+21.0%
- Gross Margin30.06%-3.4%
- EBITDA Margin22.25%-1.4%
- Operating Margin21.14%-0.2%
- Net Margin17.83%-7.0%
- ROE70.23%+20.2%
MEDP Key Insights
Medpace Holdings, Inc. (MEDP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 62.8%
- ✓Strong 5Y profit CAGR of 25.4%
- ✓FCF machine: 26.9% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 22.3%
- ✓Share count reduced 7.8% through buybacks
✗Weaknesses
- ✗Expensive at 29.6x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MEDP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MEDP Price & Volume
Medpace Holdings, Inc. (MEDP) stock price & volume — 10-year historical chart
Loading chart...
MEDP Growth Metrics
Medpace Holdings, Inc. (MEDP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.56%
5 Years22.27%
3 Years20.12%
TTM24.19%
Profit CAGR
10 Years-
5 Years25.42%
3 Years22.51%
TTM10.57%
EPS CAGR
10 Years-
5 Years31.81%
3 Years28.04%
TTM21.53%
Return on Capital
10 Years28.74%
5 Years44.63%
3 Years56.68%
Last Year65.72%
MEDP Recent Earnings
Medpace Holdings, Inc. (MEDP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 22, 2026Metric
Actual
Est
EPS
$4.28+14.4%
$3.74
Rev
$707M+1.3%
$698M
Q1 2026
Feb 9, 2026Metric
Actual
Est
EPS
$4.67+11.5%
$4.19
Rev
$708M+2.8%
$689M
Q4 2025
Oct 22, 2025Metric
Actual
Est
EPS
$3.86+9.3%
$3.53
Rev
$660M+2.9%
$641M
Q3 2025
Jul 21, 2025Metric
Actual
Est
EPS
$3.10+4.0%
$2.98
Rev
$603M+12.0%
$539M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 22, 2026 | $4.28vs $3.74+14.4% | $707Mvs $698M+1.3% |
| Q1 2026 | Feb 9, 2026 | $4.67vs $4.19+11.5% | $708Mvs $689M+2.8% |
| Q4 2025 | Oct 22, 2025 | $3.86vs $3.53+9.3% | $660Mvs $641M+2.9% |
| Q3 2025 | Jul 21, 2025 | $3.10vs $2.98+4.0% | $603Mvs $539M+12.0% |
Based on last 12 quarters of dataView full earnings history →
MEDP Peer Comparison
Medpace Holdings, Inc. (MEDP) competitors in Contract Research and Preclinical Services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ICLR | 11.18B | 146.00 | 50.34 | -0.37% | 5.98% | 5.2% | 0.39 | |
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 | |
 PRA | 1.27B | 24.65 | 24.90 | -2.67% | 6.04% | 4.95% | 0.32 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 IQV | 28.47B | 167.77 | 21.40 | 5.87% | 8.33% | 22.11% | 2.44 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare MEDP vs Peers
Medpace Holdings, Inc. (MEDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MEDP Income Statement
Medpace Holdings, Inc. (MEDP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 436.15M | 704.59M | 860.97M | 925.92M | 1.14B | 1.46B | 1.89B | 2.11B | 2.53B | 2.68B |
Revenue Growth % | 3.46% | 61.55% | 22.19% | 7.54% | 23.38% | 27.8% | 29.17% | 11.84% | 19.97% | 24.19% |
Cost of Goods Sold | 261.46M | 489.06M | 615.27M | 647.2M | 814.22M | 1.03B | 1.36B | 1.45B | 1.77B | 1.9B |
COGS % of Revenue | 59.95% | 69.41% | 71.46% | 69.9% | 71.27% | 70.38% | 72.19% | 68.88% | 69.94% | - |
Gross Profit | 174.69M▲ 0% | 215.53M▲ 23.4% | 245.7M▲ 14.0% | 278.73M▲ 13.4% | 328.15M▲ 17.7% | 432.44M▲ 31.8% | 524.5M▲ 21.3% | 656.3M▲ 25.1% | 760.62M▲ 15.9% | 778.59M▲ 0% |
Gross Margin % | 40.05% | 30.59% | 28.54% | 30.1% | 28.73% | 29.62% | 27.81% | 31.12% | 30.06% | 29.07% |
Gross Profit Growth % | 1.5% | 23.38% | 14% | 13.44% | 17.73% | 31.78% | 21.29% | 25.13% | 15.89% | - |
Operating Expenses | 109.83M | 114.48M | 118.43M | 111.68M | 129.54M | 153.74M | 187.68M | 209.44M | 225.68M | 215.68M |
OpEx % of Revenue | 25.18% | 16.25% | 13.76% | 12.06% | 11.34% | 10.53% | 9.95% | 9.93% | 8.92% | - |
Selling, General & Admin | 63.36M | 75.68M | 95.25M | 92.16M | 108.42M | 131.4M | 161.35M | 180.18M | 197.56M | 187.58M |
SG&A % of Revenue | 14.53% | 10.74% | 11.06% | 9.95% | 9.49% | 9% | 8.56% | 8.54% | 7.81% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 46.47M | 38.8M | 23.19M | 19.53M | 21.12M | 22.34M | 26.33M | 29.25M | 28.12M | 4M |
Operating Income | 64.86M▲ 0% | 101.05M▲ 55.8% | 127.26M▲ 25.9% | 167.04M▲ 31.3% | 198.62M▲ 18.9% | 278.7M▲ 40.3% | 336.82M▲ 20.9% | 446.87M▲ 32.7% | 534.93M▲ 19.7% | 562.91M▲ 0% |
Operating Margin % | 14.87% | 14.34% | 14.78% | 18.04% | 17.39% | 19.09% | 17.86% | 21.19% | 21.14% | 21.02% |
Operating Income Growth % | 23.56% | 55.8% | 25.94% | 31.26% | 18.9% | 40.32% | 20.86% | 32.67% | 19.71% | - |
EBITDA | 111.33M | 139.85M | 150.45M | 186.57M | 219.73M | 301.04M | 363.15M | 476.12M | 563.06M | 577.07M |
EBITDA Margin % | 25.53% | 19.85% | 17.47% | 20.15% | 19.23% | 20.62% | 19.26% | 22.58% | 22.25% | 21.55% |
EBITDA Growth % | 0.66% | 25.61% | 7.58% | 24.01% | 17.78% | 37% | 20.63% | 31.11% | 18.26% | 18.86% |
D&A (Non-Cash Add-back) | 46.47M | 38.8M | 23.19M | 19.53M | 21.12M | 22.34M | 26.33M | 29.25M | 28.12M | 14.16M |
EBIT | 64.5M | 101.05M | 127.26M | 167.04M | 198.62M | 278.7M | 336.82M | 446.87M | 542.38M | 565.71M |
Net Interest Income | -7.56M | -8.16M | -1.57M | 307K | -105K | -2.9M | -488K | 25M | 0 | 7.71M |
Interest Income | 0 | 0 | 0 | 307K | 0 | 0 | 0 | 25M | 0 | 7.71M |
Interest Expense | 7.56M | 8.16M | 1.57M | 0 | 105K | 2.9M | 488K | 0 | 0 | 0 |
Other Income/Expense | -7.91M | -7.1M | -2.43M | 1.49M | 3.24M | 4.16M | -1.14M | 29.05M | 7.44M | 8.88M |
Pretax Income | 56.95M▲ 0% | 93.95M▲ 65.0% | 124.83M▲ 32.9% | 168.53M▲ 35.0% | 201.85M▲ 19.8% | 282.86M▲ 40.1% | 335.68M▲ 18.7% | 475.92M▲ 41.8% | 542.38M▲ 14.0% | 571.8M▲ 0% |
Pretax Margin % | 13.06% | 13.33% | 14.5% | 18.2% | 17.67% | 19.37% | 17.8% | 22.57% | 21.44% | 21.35% |
Income Tax | 17.82M | 20.77M | 24.39M | 23.15M | 20M | 37.49M | 52.87M | 71.54M | 91.25M | 111.4M |
Effective Tax Rate % | 31.3% | 22.1% | 19.54% | 13.74% | 9.91% | 13.25% | 15.75% | 15.03% | 16.82% | 19.48% |
Net Income | 39.12M▲ 0% | 73.19M▲ 87.1% | 100.44M▲ 37.2% | 145.38M▲ 44.7% | 181.85M▲ 25.1% | 245.37M▲ 34.9% | 282.81M▲ 15.3% | 404.39M▲ 43.0% | 451.12M▲ 11.6% | 460.4M▲ 0% |
Net Margin % | 8.97% | 10.39% | 11.67% | 15.7% | 15.92% | 16.81% | 15% | 19.17% | 17.83% | 17.19% |
Net Income Growth % | 191.41% | 87.07% | 37.25% | 44.74% | 25.08% | 34.93% | 15.26% | 42.99% | 11.56% | 10.57% |
Net Income (Continuing) | 39.12M | 73.19M | 100.44M | 145.38M | 181.85M | 245.37M | 282.81M | 404.39M | 451.12M | 460.4M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.98▲ 0% | 1.97▲ 101.0% | 2.67▲ 35.5% | 3.84▲ 43.8% | 4.81▲ 25.3% | 7.28▲ 51.4% | 8.88▲ 22.0% | 12.63▲ 42.2% | 15.28▲ 21.0% | 15.90▲ 0% |
EPS Growth % | 164.86% | 101.02% | 35.53% | 43.82% | 25.26% | 51.35% | 21.98% | 42.23% | 20.98% | 21.53% |
EPS (Basic) | 1.00 | 2.05 | 2.79 | 4.07 | 5.06 | 7.57 | 9.20 | 13.06 | 15.64 | - |
Diluted Shares Outstanding | 39.84M | 36.91M | 37.58M | 37.71M | 37.7M | 33.67M | 31.84M | 32.01M | 29.53M | 28.96M |
Basic Shares Outstanding | 39.06M | 35.55M | 35.88M | 35.63M | 35.86M | 32.39M | 30.72M | 30.96M | 28.85M | 28.45M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MEDP Balance Sheet
Medpace Holdings, Inc. (MEDP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 129.97M | 178.11M | 317.03M | 473.65M | 690.91M | 333.96M | 593.83M | 1.03B | 989.62M | 1.14B |
Cash & Short-Term Investments | 26.48M | 23.27M | 131.92M | 277.77M | 461.3M | 28.27M | 245.45M | 669.44M | 497.05M | 652.68M |
Cash Only | 26.48M | 23.27M | 131.92M | 277.77M | 461.3M | 28.27M | 245.45M | 669.44M | 497.05M | 652.68M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 83.08M | 133.45M | 155.66M | 160.96M | 186.43M | 253.4M | 298.4M | 296.44M | 402.08M | 394.58M |
Days Sales Outstanding | 69.53 | 69.13 | 65.99 | 63.45 | 59.57 | 63.35 | 57.75 | 51.3 | 58 | 52.73 |
Inventory | 7K | 7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 0.01 | 0.01 | - | - | - | - | - | - | - | - |
Other Current Assets | 7K | 7K | 0 | 0 | 0 | 52.29M | 49.98M | 63.35M | 90.5M | 91.79M |
Total Non-Current Assets | 820.75M | 789.82M | 826.04M | 917.03M | 969.02M | 1.02B | 1.06B | 1.07B | 985.85M | 990.56M |
Property, Plant & Equipment | 48.74M | 52.26M | 99.44M | 198.83M | 222.71M | 248.92M | 265.39M | 252.26M | 248.87M | 263.36M |
Fixed Asset Turnover | 8.95x | 13.48x | 8.66x | 4.66x | 5.13x | 5.87x | 7.11x | 8.36x | 10.17x | 10.36x |
Goodwill | 660.98M | 660.98M | 662.4M | 662.4M | 662.4M | 662.4M | 662.4M | 662.4M | 662.4M | 662.4M |
Intangible Assets | 98.74M | 69.18M | 54.35M | 46.47M | 41.36M | 38.01M | 35.81M | 34.37M | 33.42M | 33.27M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5.94M | 6.69M | 9.48M | 8.79M | 17.42M | 21.13M | 24.97M | 22.25M | 21.94M | 28.32M |
Total Assets | 950.72M▲ 0% | 967.93M▲ 1.8% | 1.14B▲ 18.1% | 1.39B▲ 21.7% | 1.66B▲ 19.4% | 1.35B▼ 18.5% | 1.66B▲ 22.5% | 2.1B▲ 26.8% | 1.98B▼ 6.0% | 2.13B▲ 0% |
Asset Turnover | 0.46x | 0.73x | 0.75x | 0.67x | 0.69x | 1.08x | 1.14x | 1.00x | 1.28x | 1.44x |
Asset Growth % | -2.9% | 1.81% | 18.09% | 21.66% | 19.36% | -18.52% | 22.5% | 26.8% | -5.97% | -27.76% |
Total Current Liabilities | 192.71M | 257.03M | 343M | 440.11M | 557.22M | 803.47M | 925.13M | 1.1B | 1.34B | 1.35B |
Accounts Payable | 16.67M | 16.74M | 22.4M | 26.55M | 25.68M | 33.07M | 31.87M | 32.53M | 28.14M | 34.43M |
Days Payables Outstanding | 23.28 | 12.49 | 13.29 | 14.97 | 11.51 | 11.75 | 8.54 | 8.17 | 5.8 | 6.36 |
Short-Term Debt | 16.5M | 0 | 0 | 0 | 0 | 50M | 0 | 23.29M | 23.21M | 244.51M |
Deferred Revenue (Current) | 73.76M | 147.94M | 192.36M | 255.66M | 344.64M | 462.73M | 559.86M | 710.59M | 854.39M | 2.5B |
Other Current Liabilities | 81.81M | 36.2M | 53.11M | 63.73M | 85.46M | 118.74M | 116.26M | 115.27M | 357.87M | 1.07B |
Current Ratio | 0.67x | 0.69x | 0.92x | 1.08x | 1.24x | 0.42x | 0.64x | 0.93x | 0.74x | 0.85x |
Quick Ratio | 0.67x | 0.69x | 0.92x | 1.08x | 1.24x | 0.42x | 0.64x | 0.93x | 0.74x | 0.85x |
Cash Conversion Cycle | 46.26 | 56.64 | - | - | - | - | - | - | - | 46.37 |
Total Non-Current Liabilities | 254.48M | 121.2M | 73.79M | 144.79M | 149.79M | 162.64M | 172.75M | 170.77M | 172.65M | 186.28M |
Long-Term Debt | 205.11M | 79.72M | 0 | 0 | 0 | 0 | 0 | 0 | 113.64M | 122.26M |
Capital Lease Obligations | 0 | 0 | 45.21M | 115.14M | 130.97M | 138.87M | 142.12M | 126.23M | 113.64M | 479.91M |
Deferred Tax Liabilities | 560K | 439K | 12.85M | 13.55M | 1.08M | 1.07M | 2.4M | 1.8M | 9.65M | 17.5M |
Other Non-Current Liabilities | 48.81M | 41.04M | 15.72M | 16.09M | 17.75M | 22.7M | 28.22M | 42.73M | -64.29M | 60.1M |
Total Liabilities | 447.19M | 378.23M | 416.79M | 584.9M | 707.01M | 966.11M | 1.1B | 1.28B | 1.52B | 1.53B |
Total Debt | 221.61M | 79.72M | 45.21M | 115.14M | 130.97M | 188.87M | 142.12M | 149.52M | 250.5M | 122.26M |
Net Debt | 195.13M | 56.45M | -86.71M | -162.62M | -330.34M | 160.6M | -103.33M | -519.91M | -246.55M | -530.42M |
Debt / Equity | 0.44x | 0.14x | 0.06x | 0.14x | 0.14x | 0.49x | 0.25x | 0.18x | 0.55x | 0.20x |
Debt / EBITDA | 1.99x | 0.57x | 0.30x | 0.62x | 0.60x | 0.63x | 0.39x | 0.31x | 0.44x | 0.21x |
Net Debt / EBITDA | 1.75x | 0.40x | -0.58x | -0.87x | -1.50x | 0.53x | -0.28x | -1.09x | -0.44x | -0.92x |
Interest Coverage | 8.53x | 12.39x | 81.16x | - | 1891.57x | 95.94x | 690.22x | - | - | - |
Total Equity | 503.53M▲ 0% | 589.7M▲ 17.1% | 726.28M▲ 23.2% | 805.78M▲ 10.9% | 952.93M▲ 18.3% | 386.39M▼ 59.5% | 558.95M▲ 44.7% | 825.54M▲ 47.7% | 459.07M▼ 44.4% | 598.31M▲ 0% |
Equity Growth % | -17.55% | 17.11% | 23.16% | 10.95% | 18.26% | -59.45% | 44.66% | 47.7% | -44.39% | -187.71% |
Book Value per Share | 12.64 | 15.98 | 19.33 | 21.37 | 25.28 | 11.48 | 17.55 | 25.79 | 15.55 | 20.66 |
Total Shareholders' Equity | 503.53M | 589.7M | 726.28M | 805.78M | 952.93M | 386.39M | 558.95M | 825.54M | 459.07M | 598.31M |
Common Stock | 355K | 356K | 360K | 355K | 360K | 309K | 308K | 306K | 284K | 286K |
Retained Earnings | -120.4M | -41.49M | 68.11M | 115.23M | 234.98M | -359.83M | -221.65M | 8.17M | -459.98M | -336.11M |
Treasury Stock | -6.03M | -6.03M | -6.03M | -5.58M | -5.43M | -12.5M | -12.32M | -12.23M | -12.16M | -12.16M |
Accumulated OCI | -734K | -2.52M | -2.74M | -131K | -4.85M | -12.39M | -10.07M | -14.74M | -4.91M | -7.12M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MEDP Cash Flow Statement
Medpace Holdings, Inc. (MEDP) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 97.39M | 156.58M | 201.87M | 258.68M | 263.33M | 388.05M | 433.37M | 608.82M | 713.22M | 739.17M |
Operating CF Margin % | 22.33% | 22.22% | 23.45% | 27.94% | 23.05% | 26.58% | 22.98% | 28.87% | 28.19% | - |
Operating CF Growth % | 6.16% | 60.79% | 28.92% | 28.14% | 1.8% | 47.36% | 11.68% | 40.48% | 17.15% | 114.43% |
Net Income | 39.12M | 73.19M | 100.44M | 145.38M | 181.85M | 245.37M | 282.81M | 404.39M | 451.12M | 460.4M |
Depreciation & Amortization | 46.47M | 38.8M | 23.19M | 19.53M | 21.12M | 22.34M | 26.33M | 29.25M | 27.18M | 27.24M |
Stock-Based Compensation | 4.46M | 6.5M | 20.74M | 13.78M | 14.47M | 21.41M | 20.52M | 25.51M | 34.79M | 12.27M |
Deferred Taxes | 3.24M | 3.94M | 10.05M | 527K | -37.11M | -23.01M | -25.12M | -26.63M | 80.77M | 98.57M |
Other Non-Cash Items | -8.79M | -5.44M | 11.86M | 13.2M | 16.3M | 15.89M | 22.35M | 19.11M | 23.09M | 34.23M |
Working Capital Changes | 12.88M | 39.6M | 35.59M | 66.26M | 66.71M | 106.06M | 106.49M | 157.18M | 96.28M | 106.47M |
Change in Receivables | -2.9M | -27.05M | -21.26M | -5.53M | -24.98M | -66.92M | -48.28M | 2.24M | -106.22M | -96.32M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 4.82M | 1.34M | 4.73M | -2.6M | 1.87M | 6.43M | 1.05M | -2.96M | 2.63M | -8.01M |
Cash from Investing | -12.24M | -16.97M | -19.14M | -31.21M | -31.36M | -38.74M | -34.63M | -28.31M | -31.14M | -27.9M |
Capital Expenditures | -11.72M | -16.02M | -17.91M | -31.34M | -28.27M | -36.88M | -36.65M | -36.55M | 0 | 5.46M |
CapEx % of Revenue | 2.69% | 2.27% | 2.08% | 3.38% | 2.47% | 2.53% | 1.94% | 1.73% | 1.24% | 0.2% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -513K | -949K | -1.23M | 126K | -3.09M | -1.86M | 2.02M | 8.24M | -31.14M | -33.36M |
Cash from Financing | -97.83M | -141.58M | -73.92M | -82.28M | -44.45M | -775.77M | -182.64M | -154.01M | -860.39M | -501.75M |
Debt Issued (Net) | 57.63M | -142.19M | -80.44M | 0 | 0 | 50M | -50M | 0 | 0 | 0 |
Equity Issued (Net) | -155.58M | 0 | 0 | -98.27M | -62.1M | -847.85M | -144.02M | -169.87M | -860.39M | -510.09M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -155.58M | 0 | 0 | -98.27M | -62.1M | -847.85M | -144.02M | -169.87M | -917.39M | -545.49M |
Other Financing | 130K | 608K | 6.52M | 15.99M | 17.64M | 22.07M | 11.38M | 15.86M | 0 | 8.34M |
Net Change in Cash | -10.91M▲ 0% | -3.21M▲ 70.6% | 108.64M▲ 3484.4% | 145.85M▲ 34.2% | 183.54M▲ 25.8% | -433.04M▼ 335.9% | 217.18M▲ 150.2% | 423.99M▲ 95.2% | -172.39M▼ 140.7% | 211.25M▲ 0% |
Free Cash Flow | 85.09M▲ 0% | 140.56M▲ 65.2% | 183.96M▲ 30.9% | 227.34M▲ 23.6% | 235.06M▲ 3.4% | 351.17M▲ 49.4% | 396.73M▲ 13.0% | 572.27M▲ 44.2% | 681.87M▲ 19.2% | 744.63M▲ 0% |
FCF Margin % | 19.51% | 19.95% | 21.37% | 24.55% | 20.58% | 24.05% | 21.04% | 27.13% | 26.95% | 27.8% |
FCF Growth % | 8.82% | 65.19% | 30.87% | 23.58% | 3.4% | 49.4% | 12.97% | 44.25% | 19.15% | 37.66% |
FCF per Share | 2.14 | 3.81 | 4.90 | 6.03 | 6.24 | 10.43 | 12.46 | 17.88 | 23.09 | 25.71 |
FCF Conversion (FCF/Net Income) | 2.49x | 2.14x | 2.01x | 1.78x | 1.45x | 1.58x | 1.53x | 1.51x | 1.58x | 1.62x |
Interest Paid | 6.89M | 7.59M | 1.49M | 104K | 123K | 2.94M | 3.06M | 171K | 0 | 0 |
Taxes Paid | 17.18M | 23.31M | 13.23M | 23.11M | 56.24M | 50.16M | 76.35M | 83.57M | 0 | 0 |
MEDP Key Ratios
Medpace Holdings, Inc. (MEDP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 7.02% | 13.39% | 15.27% | 18.98% | 20.68% | 36.64% | 59.83% | 58.42% | 70.23% | 120.89% |
Return on Invested Capital (ROIC) | 6.78% | 11.27% | 14.85% | 19.53% | 23.54% | 35.74% | 50.39% | 88.05% | 154.86% | 238.35% |
Gross Margin | 40.05% | 30.59% | 28.54% | 30.1% | 28.73% | 29.62% | 27.81% | 31.12% | 30.06% | 29.07% |
Net Margin | 8.97% | 10.39% | 11.67% | 15.7% | 15.92% | 16.81% | 15% | 19.17% | 17.83% | 17.19% |
Debt / Equity | 0.44x | 0.14x | 0.06x | 0.14x | 0.14x | 0.49x | 0.25x | 0.18x | 0.55x | 0.20x |
Interest Coverage | 8.53x | 12.39x | 81.16x | - | 1891.57x | 95.94x | 690.22x | - | - | - |
FCF Conversion | 2.49x | 2.14x | 2.01x | 1.78x | 1.45x | 1.58x | 1.53x | 1.51x | 1.58x | 1.62x |
Revenue Growth | 3.46% | 61.55% | 22.19% | 7.54% | 23.38% | 27.8% | 29.17% | 11.84% | 19.97% | 24.19% |
Related:MEDP Dividend History·MEDP Revenue History·MEDP Price History·MEDP P/E History·MEDP Financial Ratios·MEDP Institutional Holders
MEDP SEC Filings & Documents
Medpace Holdings, Inc. (MEDP) SEC filings — annual & quarterly reports (10-K, 10-Q)
MEDP Frequently Asked Questions
Medpace Holdings, Inc. (MEDP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Medpace Holdings, Inc. (MEDP) reported $2.68B in revenue for fiscal year 2025. This represents a 823% increase from $290.0M in 2014.
Medpace Holdings, Inc. (MEDP) grew revenue by 20.0% over the past year. This is strong growth.
Yes, Medpace Holdings, Inc. (MEDP) is profitable, generating $460.4M in net income for fiscal year 2025 (17.8% net margin).
Dividend & Returns
Medpace Holdings, Inc. (MEDP) has a return on equity (ROE) of 70.2%. This is excellent, indicating efficient use of shareholder capital.
Medpace Holdings, Inc. (MEDP) generated $744.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.